The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson’s disease
Background: NICE in England, and ICER in the US both use cost-utility analyses (CUA) and budget impact analyses (BIA) to assess value for money and affordability, however the thresholds used differ greatly. Objective: To perform a cross-country comparison of the results of the CUA and BIA and detail...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2018-01-01
|
| Series: | Journal of Market Access & Health Policy |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/20016689.2018.1500419 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849684383676497920 |
|---|---|
| author | Jesper Jørgensen Spiros Servos Panos Kefalas |
| author_facet | Jesper Jørgensen Spiros Servos Panos Kefalas |
| author_sort | Jesper Jørgensen |
| collection | DOAJ |
| description | Background: NICE in England, and ICER in the US both use cost-utility analyses (CUA) and budget impact analyses (BIA) to assess value for money and affordability, however the thresholds used differ greatly. Objective: To perform a cross-country comparison of the results of the CUA and BIA and detail the implications for reimbursed price and volumes, for a novel gene therapy for Parkinson’s disease (PD). Methods: A Markov model was built to perform country-specific CUAs and BIAs Findings: The US ceiling price identified through CUA is ~ 1.8 times higher than in England (aligning to our previous US/UK price comparison analysis of high-cost drugs). However, the net budget impact corresponding to these price levels would limit number of patients treated in order not to exceed the BIA threshold. Performance-based annuity payments can increase patient access at launch without exceeding the thresholds while reducing payers’ data uncertainty. Conclusion: Our cost-utility analysis in PD shows a difference in price potential between the US and England that aligns with what is observed in practice for other high-cost drugs. Furthermore, the budget impact threshold operational in England imposes a greater downwards pressure on price and/or volumes than the one applied by ICER in the US. |
| format | Article |
| id | doaj-art-c17a65ddee2144eda3fc43b9cb4bfe77 |
| institution | DOAJ |
| issn | 2001-6689 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Market Access & Health Policy |
| spelling | doaj-art-c17a65ddee2144eda3fc43b9cb4bfe772025-08-20T03:23:29ZengMDPI AGJournal of Market Access & Health Policy2001-66892018-01-016110.1080/20016689.2018.15004191500419The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson’s diseaseJesper Jørgensen0Spiros Servos1Panos Kefalas2Cell and Gene Therapy CatapultOxford BioMedica (UK)Cell and Gene Therapy CatapultBackground: NICE in England, and ICER in the US both use cost-utility analyses (CUA) and budget impact analyses (BIA) to assess value for money and affordability, however the thresholds used differ greatly. Objective: To perform a cross-country comparison of the results of the CUA and BIA and detail the implications for reimbursed price and volumes, for a novel gene therapy for Parkinson’s disease (PD). Methods: A Markov model was built to perform country-specific CUAs and BIAs Findings: The US ceiling price identified through CUA is ~ 1.8 times higher than in England (aligning to our previous US/UK price comparison analysis of high-cost drugs). However, the net budget impact corresponding to these price levels would limit number of patients treated in order not to exceed the BIA threshold. Performance-based annuity payments can increase patient access at launch without exceeding the thresholds while reducing payers’ data uncertainty. Conclusion: Our cost-utility analysis in PD shows a difference in price potential between the US and England that aligns with what is observed in practice for other high-cost drugs. Furthermore, the budget impact threshold operational in England imposes a greater downwards pressure on price and/or volumes than the one applied by ICER in the US.http://dx.doi.org/10.1080/20016689.2018.1500419Gene therapyParkinson’s diseasecost-utility analysisbudget impact analysispricing and reimbursementpatient accessEnglandUnited Kingdom (UK) |
| spellingShingle | Jesper Jørgensen Spiros Servos Panos Kefalas The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson’s disease Journal of Market Access & Health Policy Gene therapy Parkinson’s disease cost-utility analysis budget impact analysis pricing and reimbursement patient access England United Kingdom (UK) |
| title | The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson’s disease |
| title_full | The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson’s disease |
| title_fullStr | The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson’s disease |
| title_full_unstemmed | The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson’s disease |
| title_short | The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson’s disease |
| title_sort | potential price and access implications of the cost utility and budget impact methodologies applied by nice in england and icer in the us for a novel gene therapy in parkinson s disease |
| topic | Gene therapy Parkinson’s disease cost-utility analysis budget impact analysis pricing and reimbursement patient access England United Kingdom (UK) |
| url | http://dx.doi.org/10.1080/20016689.2018.1500419 |
| work_keys_str_mv | AT jesperjørgensen thepotentialpriceandaccessimplicationsofthecostutilityandbudgetimpactmethodologiesappliedbyniceinenglandandicerintheusforanovelgenetherapyinparkinsonsdisease AT spirosservos thepotentialpriceandaccessimplicationsofthecostutilityandbudgetimpactmethodologiesappliedbyniceinenglandandicerintheusforanovelgenetherapyinparkinsonsdisease AT panoskefalas thepotentialpriceandaccessimplicationsofthecostutilityandbudgetimpactmethodologiesappliedbyniceinenglandandicerintheusforanovelgenetherapyinparkinsonsdisease AT jesperjørgensen potentialpriceandaccessimplicationsofthecostutilityandbudgetimpactmethodologiesappliedbyniceinenglandandicerintheusforanovelgenetherapyinparkinsonsdisease AT spirosservos potentialpriceandaccessimplicationsofthecostutilityandbudgetimpactmethodologiesappliedbyniceinenglandandicerintheusforanovelgenetherapyinparkinsonsdisease AT panoskefalas potentialpriceandaccessimplicationsofthecostutilityandbudgetimpactmethodologiesappliedbyniceinenglandandicerintheusforanovelgenetherapyinparkinsonsdisease |